Revised SPCs: Strensiq (asfotase alfa) 40mg/ml and 100 mg/ml solution for injection

Injection site cellulitis, increased tendency to bruise, and nephrolithiasis have been added to SPCs as common ADRs. SPCs highlight safety/efficacy in elderly, renal and hepatic impairment have not been established so no specific dose regimen can be recommended for these groups.


electronic Medicines compendium